TellmeGen
a clinical-grade DTC platform offering the TellmeGen Advanced panel (around EUR 149) and the Ultra 30x WGS test that analyzes the full genome for common and rare disease risk, with pharmacogenomic drug-response reporting under IVDR.
- Country
- Spain
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| DTC genetic testing | diagnostics-medtech | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.